Zacks.com Announces That Nadine Wong Highlights Celgene

Business Wire, Dec 21, 2004

CHICAGO -- Nadine Wong, editor of the BioTech Stock Report newsletter, discusses a biotech company that has been the victim of controversial news, leading to share price decreases. Read about Celgene (NASDAQ:CELG) and find out why, based on fundamentals, this company should be a good investment over the long-term. Click here for the full story exclusively on Zacks.com: http://at.zacks.com/?id=84

E[acute accent]Highlights from the December 20th Featured Expert column by Nadine Wong includes:

E[acute accent]Concerns regarding Revlimid's safety in the myleodyoplastic syndrome (MDS) (5q minus) trial have led to the recent pull back in Celgene's (NASDAQ:CELG) share price. The reports of patient deaths in this trial raised questions concerning the drug's safety. If any of these patient deaths are drug-related, it casts serious doubts on the drug's approvability. E[acute accent]While the company has remained silent about these reports, the lead investigator of the trial has dismissed the notion that the patient deaths are directly linked to the drug. The company did confirm that the Drug Safety Monitoring Board (DSMB) of the trial did not conclude that any patient death is related to the drug. E[acute accent]Despite the concerns over the safety of Revlimid, the Thalomid/Revlimid franchise is a potential blockbuster franchise for Celgene. Investors should expect continued volatility in the stock based on Revlimid's aggressive filing strategy as a treatment in MDS. The stock eventually will recover some of the losses experienced due to the controversies. For the longer-term, Celgene is a good investment because of the company's strong revenue, EPS growth and product pipeline.

E[acute accent]Read Nadine Wong's complete commentary by clicking: http://at.zacks.com/?id=85

E[acute accent]About Zacks Featured Experts

E[acute accent]Successful investing requires professional advice from knowledgeable experts who can help investors achieve their financial goals in good markets and improve their portfolios, especially in bad ones. That is why Zacks Investment Research has assembled the best investment experts in the business to offer their powerful advisory newsletters on all the major investment topics: Stocks, Mutual Funds, Bonds, Options, Futures etc. E[acute accent]Additional recommendations from Zacks.com Featured Experts are highlighted in the free investment newsletter, Profit from the Pros. Each issue highlights several Featured Experts in this free e-mail newsletter. Register for a free subscription to "Profit from the Pros" at: http://at.zacks.com/?id=86

E[acute accent]About Zacks

E[acute accent]Zacks.com is a property of Zacks Investment Research, Inc., which was formed in 1978 to compile, analyze, and distribute investment research to both institutional and individual investors. The guiding principle behind Zacks work is the belief that investment experts, such as brokerage analysts and investment newsletter writers, have superior knowledge about how to invest successfully. The goal is to unlock these pros' profitable insights for individual investors hard-pressed to find this valuable information in one source. A free subscription to "Profit from the Pros" weekly e-mail newsletter provides the best way to use these experts' insights for more profitable investing. Register now for a free subscription to the Profit from the Pros newsletter at http://at.zacks.com/?id=87 E[acute accent]Zacks Investment Research is under common control with affiliated entities (including a broker-dealer and an investment adviser), which may engage in transactions involving the foregoing securities for the clients of such affiliates.

E[acute accent]Disclaimer: Past performance does not guarantee future results. Investors should always research companies and securities before making any investments. Nothing herein should be construed as an offer or solicitation to buy or sell any security.